LightDark Log in Sign up

‹ Back to screener

JUBLPHARMA.NS Jubilant Pharmova Ltd.

Healthcare

Price history

1M 6M 1Y 3Y Max
2021-08-23 ₹599.05
2026-08-21 ₹889.50
Change over window +48.49%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 43.1%
Trailing 20-day average 51.9%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 124044 53437 43.08%
2026-08-27 86026 46699 54.28%
2026-08-26 108892 65507 60.16%
2026-08-25 191721 73508 38.34%
2026-08-24 1931803 673640 34.87%
2026-08-21 229193 126000 54.98%
2026-08-20 181295 95036 52.42%
2026-08-19 944269 712444 75.45%
2026-08-18 174172 101695 58.39%
2026-08-17 309691 151989 49.08%
2026-08-14 221700 127681 57.59%
2026-08-13 207364 86971 41.94%
2026-08-12 697403 269424 38.63%
2026-08-11 886877 306109 34.52%
2026-08-10 357574 200167 55.98%
2026-08-07 168059 91244 54.29%
2026-08-06 158398 103008 65.03%
2026-08-05 71119 38734 54.46%
2026-08-04 50913 29055 57.07%
2026-08-03 204728 118919 58.09%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers JUBLPHARMA.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
12 Mar 2026 Jubilant Employees Welfare Trust - Sell ESOP 11304 9278888 0.56% XBRL
01 Oct 2025 Jubilant Employees Welfare Trust Other Buy Market Purchase 11319 12187469 0.64% XBRL
30 Sep 2025 Jubilant Employees Welfare Trust Other Buy Market Purchase 50676 54205958 0.58% XBRL
30 Sep 2025 Jubilant Employees Welfare Trust Other Buy Market Purchase 20000 20785000 0.60% XBRL
30 Sep 2025 Jubilant Employees Welfare Trust Other Buy Market Purchase 57181 60404402 0.63% XBRL
24 Sep 2025 Jubilant Employees Welfare Trust Other Buy Market Purchase 35000 38774207 0.55% XBRL
14 Aug 2025 SPB Trustee Company Private Limited and SS Trustee Company Private Limited Promoter Group Pledge Pledge Creation 2050000 2208875000 20.08% XBRL
14 Aug 2025 HSB Trustee Company Private Limited and HS Trustee Company Private Limited Promoter Group Pledge Pledge Creation 2050000 2208875000 19.00% XBRL
16 Jun 2025 SPB Trustee Company Private Limited and SS Trustee Company Private Limited Promoter Group Sell Others 700000 742000000 20.08% XBRL
16 Jun 2025 Nikita Resources Private Limited Promoter Group Sell Others 1962434 2080910065 0.97% XBRL
16 Jun 2025 Jubilant Enpro Private Limited Promoter Group Sell Others 2116000 2242960000 0.00% XBRL
20 Sep 2024 Jubilant Employees Welfare Trust Other Buy Market Purchase 36025 43786664 0.55% XBRL
20 Sep 2024 Jubilant Employees Welfare Trust Other Sell ESOP 3542 4319823 0.53% XBRL
20 Sep 2024 Jubilant Employees Welfare Trust Other Buy Market Purchase 10028 12177179 0.56% XBRL
17 Sep 2024 Jubilant Employees Welfare Trust Other Sell ESOP 6877 8190507 0.54% XBRL
10 Sep 2024 Jubilant Employees Welfare Trust Other Sell ESOP 18045 16920797 0.54% XBRL
05 Sep 2024 Jubilant Employees Welfare Trust Other Sell ESOP 39147 35895842 0.55% XBRL
29 Aug 2024 JUBILANT EMPLOYEES WELFARE TRUST Other Sell ESOP 1576 1422655 0.57% XBRL
20 Aug 2024 Jubilant Employees Welfare Trust Other Sell ESOP 22858 19725311 0.57% XBRL
26 Jun 2023 Jubilant Employees Welfare Trust Other Buy Market Purchase 33673 13380424 0.58% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers JUBLPHARMA.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹880.35 INR (live) · fetched 2026-08-23 23:33 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score

Ratios

P/E
34.90
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹880.35 / (₹3,985,000,000 / 158,000,000 shares) = ₹880.35 / ₹25.22 EPS
FY2025-26 · Annual filing
ROE
5.62%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹3,985,000,000 / ₹70,928,000,000 = 5.62%
FY2025-26 · Annual filing
Debt/Equity
0.45
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹32,195,000,000 / ₹70,928,000,000 = 0.45
FY2025-26 · Annual filing
Current Ratio
1.62
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹41,093,000,000 / ₹25,389,000,000 = 1.62
FY2025-26 · Annual filing
ROCE
8.59%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹8,854,000,000 / (₹70,928,000,000 + ₹32,195,000,000) = 8.59%
FY2025-26 · Annual filing
Dividend Yield
0.57%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹795,000,000 / 158,000,000 shares) / ₹880.35 = ₹5.03 / ₹880.35
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 8.0y actual) 1.3%
Net Profit (3y) N/A
Revenue (5y, 8.0y actual) 1.3%
Net Profit (5y) N/A
Revenue (10y, 8.0y actual) 1.3%
Net Profit (10y) N/A

Operating Margin Trend

Eroding

FY2017-18 15.3%
FY2019-20 16.7%
FY2020-21 13.8%
FY2021-22 13.0%
FY2022-23 4.1%
FY2023-24 8.8%
FY2024-25 11.9%
FY2025-26 10.7%

ROCE Trajectory

FY2017-18 N/A
FY2019-20 N/A
FY2020-21 N/A
FY2021-22 N/A
FY2022-23 3.0%
FY2023-24 6.7%
FY2024-25 9.9%
FY2025-26 8.6%

Earnings Quality

No persistent gap detected

Net Profit CAGR -0.95% vs CFO CAGR 10.01% over 4.0y (2022-03-31 → 2026-03-31); most recent year: Net Profit -52.53% vs CFO +14.43%

Sector-Relative Percentile (Healthcare)

ROE 13th
ROCE 11th
Debt/Equity 13th
P/E 72th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹1,758.60 Cr. ₹1,731.70 Cr. ₹1,752.30 Cr. ₹1,821.70 Cr. ₹1,928.80 Cr. ₹1,900.70 Cr. ₹1,966.40 Cr. ₹2,122.50 Cr. ₹2,290.00 Cr. ₹2,229.40 Cr. RevenueFromOperations
Net Profit ₹-58.60 Cr. incl. minority ₹-61.80 Cr. ₹482.10 Cr. incl. minority ₹481.80 Cr. ₹102.80 Cr. incl. minority ₹102.50 Cr. ₹100.90 Cr. incl. minority ₹100.70 Cr. ₹153.60 Cr. incl. minority ₹151.30 Cr. ₹102.90 Cr. incl. minority ₹102.50 Cr. ₹120.30 Cr. incl. minority ₹119.90 Cr. ₹55.90 Cr. incl. minority ₹55.80 Cr. ₹119.40 Cr. incl. minority ₹119.30 Cr. ₹56.50 Cr. incl. minority ₹56.40 Cr. ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers JUBLPHARMA.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent3985000000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital158000000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets41093000000.0
CurrentLiabilities25389000000.0
EquityAttributableToOwnersOfParent70928000000.0
BorrowingsCurrent + BorrowingsNoncurrent32195000000.0

My notes